Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease
Status:
Completed
Trial end date:
2021-08-10
Target enrollment:
Participant gender:
Summary
The study consists of two parts. Part I (CHICO) was designed to develop a better
understanding of the efficacy, safety and pharmacokinetics of nifurtimox in children with a
diagnosis of Chagas' disease (Trypanosoma cruzi infection) using pediatric formulations. Part
II (CHICO SECURE) was designed at request of the FDA to assess the incidence of sero-negative
conversion in children with diagnosis of Chagas' disease treated with nifurtimox.